Business
Cellular Health Market Leader Tru Niagen® Launches Online in Australia
ChromaDex Partners with Matakana Health Limited to Bring Tru Niagen to Australia LOS ANGELES, March 23, 2020 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC)
About this update from Niagen Bioscience, Inc.
[{"type":"text","content":"ChromaDex Partners with Matakana Health Limited to Bring Tru Niagen to Australia\n LOS ANGELES, March 23, 2020 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today the e-commerce launch of Tru Niagen® in Australia with distribution partner Matakana Health Limited (MHL). Tru Niagen received its listing number on the Australian Registry of Therapeutic Goods (ARTG) on January 8, 2020 (AUST L 328365). Tru Niagen is a breakthrough supplement to increase NAD+ (nicotinamide adenine dinucleotide) levels, help maintain general health and well-being, and support energy levels. “When our bodies face physiological stress, it is more important than ever that we maintain NAD+ levels to support tissue repair and general health and well-being,” says Dr. Andrew Shao, ChromaDex SVP of Global Scientific & Regulatory Affairs. “Boosting NAD+ will also help maintain energy levels to keep up with fitness routines while at home.” NAD+ levels decline with age. Maintaining healthy NAD+ levels becomes increasingly important to support one’s general health as they get older. Tru Niagen effectively boosts NAD+ levels safely as demonstrated in six published human trials. “I encourage everyone to stay active, healthy, and fit during this dynamic period around the world,” says Australian Olympic medalist and world champion swimmer James Magnussen, who is a Tru Niagen user and spokesperson. “Whether that means taking solo runs outside or watching fitness classes on your television, there are always ways to stay on top of your health in addition to maintaining a healthy diet.” ChromaDex partnered with Matakana Health to launch Tru Niagen® in New Zealand in September 2018 and recently expanded the partnership to include distribution rights in Australia. “Maintenance of NAD+ levels is fundamental to human health and well-being,” says Matakana Health CEO Kevin Glucina. “We appreciate the robust science behind Tru Niagen and are happy to launch this product in Australia with the pioneers at ChromaDex.” MHL is an established dietary supplement manufacturer and distributor in New Zealand with national and Australian distribution in both online and offline channels. The company has more than 90 lines of organic and superfood products. In December 2019, ChromaDex's patented nicotinamide riboside chloride (NR) was listed in the Therapeutic Goods (Permissible...